← SynDRA
ZOTIRACICLIB
SynDRA canonical compound SYN0028669 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | CCNT1 | CDK1 | CDK2 | CDK7 | CDK9 | FLT3 | JAK2 | MAPK7 |
|---|
| Mechanism of action | CDK inhibitor | FLT3 inhibitor | JAK inhibitor |
|---|
All known targets
- CDK2
- CDK1
- CDK7
- CDK9
- FLT3
- JAK2
- CCNT1
- MAPK7
Mechanisms of action (all sources)
- CDK1 INHIBITOR
- Cyclin-dependent kinase 1 inhibitor
- CDK2 INHIBITOR
- Cyclin-dependent kinase 2 inhibitor
- CDK7 INHIBITOR
- Cyclin-dependent kinase 7 inhibitor
- CDK9 INHIBITOR
- Cyclin-dependent kinase 9 inhibitor
- FLT3 INHIBITOR
- Tyrosine-protein kinase receptor FLT3 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
Cross-references
Synonyms
- Ex 45
- Sb-1317 free base
- Tg-02
- TG02
- EX45
- SB-1317
- SB1317
- TG-02
- TG02 (Double bond Z/E)
- UNII-40D08182TT
- CHEMBL1944698
- 40D08182TT
- C23H24N4O
- Tube011
- SB-1317 free base
- TG02 (Double bond E)
- TG02 [WHO-DD]
- SCHEMBL823947
- SCHEMBL2298965
- GTPL9095
- SCHEMBL17595943
- EX-A239
- MolPort-039-139-793
- AOB87361
- BCP07033
- ZINC68251500
- BDBM50363196
- 4029AH
- AKOS030527020
- AKOS032950000
- SB1317(TG-02)
- SB14606
- CS-0884
- compound 26h [PMID: 22148278]
- KB-80503
- HY-15166
- W-5884
- SB 1317
- RefChem:196271
Look up ZOTIRACICLIB in the interactive SynDRA portal →